Rivoceranib (Apatinib)

DRUG2 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., Fudan University

Conditions

Hepatocellular Carcinoma (HCC)Mixed Hepatocellular-cholangiocarcinoma

Phase 2

HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)

RecruitingNCT07105748

Fudan UniversityMixed Hepatocellular-cholangiocarcinoma

Start: 2025-08-15End: 2028-08-01Target: 45Updated: 2025-08-17

Phase 3

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Active, not recruitingNCT04639180

Jiangsu HengRui Medicine Co., Ltd.Hepatocellular Carcinoma (HCC)

Start: 2021-04-01End: 2026-07-31Updated: 2025-12-30